Geisinger Clinic

Geisinger Clinic, doing business as Geisinger Health Group, operates as a non-profit integrated healthcare system subsidiary of Geisinger Health System Foundation, delivering clinical research, medical surveillance, epidemiological analysis, and specialty healthcare services to federal agencies as a prime recipient and prime contractor without set-asides. Headquartered in Danville, Pennsylvania, Geisinger serves 45 counties across central and northeastern Pennsylvania and New Jersey, operating as a learning health system with robust electronic health record infrastructure and the MyCode biobank serving approximately 338,000 consented participants and one million individuals in genomic and phenotypic datasets.

Geisinger's federal contract and grant portfolio spans 502 awards (389 prime, 113 sub) valued at $37 million in potential value, with $321.3 million obligated across fiscal years 2022–2026. Activity has accelerated from 14 awards in 2022 to 37 in 2025, with 12 awards (12 customer agencies) completing within the next twenty-four months. The portfolio concentration reflects a diverse public health and research customer base rather than a single dominant funder. The Department of Justice Bureau of Prisons Federal Correctional Complex Allenwood accounts for 150 awards ($21.5 million potential value, 30% of portfolio by count), anchoring laboratory and medical services work through BPAs including DJB20104BPA08088 (9 task orders) and DJB20104BPA07088 (3 task orders). The Department of Health and Human Services, Centers for Disease Control and Prevention (Pittsburgh) follows with 4 awards ($7.9 million potential value) for disease surveillance and prevention research; the National Heart Lung and Blood Institute accounts for 39 awards across cardiovascular research and epidemiology; the National Cancer Institute carries 12 awards ($3.5 million potential value); and the Department of Veterans Affairs Veterans Health Administration (Veterans Integrated Service Network 4) represents 17 awards ($824 thousand potential value). Smaller volumes reach the National Human Genome Research Institute, National Institute of Environmental Health Sciences, SAMHSA, the Bureau of Health Professionals, and other NIH components.

Geisinger's concrete capability footprint centers on clinical research powered by electronic health record and biobank data, medical laboratory services (PSC Reference Laboratory Testing, 36 awards), and epidemiological surveillance leveraging integrated healthcare delivery. Representative prime contracts include a $1.1 million definitive contract with CDC for the Surveillance Based Lyme Disease Network (SUBLYME), concluded September 2026, conducting surveillance and research on Lyme disease; a $525 thousand CDC contract (awarded September 2023, completed September 2024) for a diabetes prevention demonstration project targeting Black communities through barbers and stylists; and a $19.5 thousand purchase order from the National Human Genome Research Institute (2022) supporting protocol research and patient recruitment. The portfolio tilts heavily toward federal grants in health research: the National Heart Lung and Blood Institute awarded $823.6 thousand (August 2026) for titin gene protein-truncating variant research assembling and harmonizing genomic and phenotypic data across three biobanks (MyCode at Geisinger, BioVU, and UK Biobank) through May 2031, and $727.6 thousand (July 2026) for aortic aneurysm detection and genetic risk assessment using deep learning and radiologic analysis through March 2030; the National Institute of Environmental Health Sciences funded a $3.4 million project grant (September 2025, through June 2029) characterizing extreme heat exposure and cardiovascular and pulmonary outcomes with Johns Hopkins University as sub-recipient; CDC awarded $998.8 thousand (September 2025) for the Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY, CFDA 93.945) through September 2027; the National Institute on Drug Abuse supported two project grants (both September 2023) totaling $1.2 million for evaluating peer recovery support programs in medication for opioid use disorder treatment through July and August 2029; SAMHSA funded $1.1 million (September 2022) for the Free2BMom opioid and substance use disorder program serving pregnant mothers and babies through September 2027; the Bureau of Health Professionals awarded $749.6 thousand (August 2023) for rural residency planning in preventive medicine and $2.6 million (July 2023) for an integrated substance use disorder training program for advanced practice providers and social workers through 2027 and 2028 respectively; and the USDA Rural Utilities Service granted $948.7 thousand (August 2023) for telemedicine infrastructure through August 2025 and $1 million (September 2022) for rural healthcare facility improvement through September 2024. Geisinger serves as prime recipient on approximately 36 federal NIH project and cooperative agreement grants focused on cardiovascular disease, genomic medicine, psychiatric precision medicine, maternal health, perinatal genomics, and health equity, with performance in Danville, Pennsylvania.

Geisinger operates as a major subcontractor to academic research leaders. The sub-award footprint spans 113 grants and contracts, with Geisinger providing genomic analysis, electronic health record data access, biobank sample provision, and site leadership for multi-institutional consortia. Prime grantees receiving Geisinger sub-awards include the University of Pennsylvania (15+ sub-awards for genomic association studies, obstructive sleep apnea research, lung cancer screening equity, and obstetric informatics), Vanderbilt University Medical Center (10+ sub-awards for rare variant discovery in cardiomyopathy, polygenic risk score integration, and obesity genomics), Pennsylvania State University (12+ sub-awards for stroke prediction, cardiovascular health, and vascular research), Baylor College of Medicine (4 sub-awards for aortic aneurysm mechanisms), the Broad Institute (3 sub-awards for genomic screening resources and diabetes genomics), the Washington University (4 sub-awards for genetic and phenotypic validation in scoliosis and cardiomyopathy), and Columbia University (3 sub-awards for maternal safety informatics). Sub-award work leverages Geisinger's MyCode cohort, DiscovEHR dataset, and integrated EHR for genetic association analyses, phenotyping, case identification, and biospecimen access.

SCI-reported invoiced revenue on federal service contracts above the $150,000 threshold totaled $3 million across FY2022–FY2025 (FY2022: $659 thousand, FY2023: $708 thousand, FY2024: $1 million, FY2025: $568 thousand), with 4.1 to 4.9 FTEs delivered as prime on covered contracts per fiscal year. Government-paid hourly rates on SCI-reportable prime contracts ran median $83.19/hr, with rates spanning $79.37/hr at the tenth percentile to $144.02/hr at the ninety-fifth percentile, reflecting mixed clinical, epidemiological, and laboratory labor. Geisinger delivered all SCI-reported prime contract hours internally with zero sub-engagement on SCI-reportable contracts. The SCI dataset represents a partial view of Geisinger's federal services activity, capturing only service contracts exceeding the $150,000 reporting threshold and excluding goods, grants, and non-federal revenue; the broader prime and sub-award footprint reflects far larger clinical research and medical surveillance delivery.